Patents Assigned to Icahn School of Medicine at Mount Sinai
  • Patent number: 11110104
    Abstract: The disclosure provides compounds having formula (I): and the pharmaceutically acceptable salts thereof, wherein R1, R2, R2?, and X are as defined as set forth in the specification, for use in treating cognitive deficits and/or psychiatric disorders, such as those associated with neurological or neurodegenerative disorders, psychiatric or mood disorders, and HIV-associated neurocognitive disorders (HAND). Compounds having formula (I) are prodrugs that release glutamine analogs, e.g., 6-diazo-5-oxo-L-norleucine (DON).
    Type: Grant
    Filed: January 31, 2018
    Date of Patent: September 7, 2021
    Assignees: The Johns Hopkins University, Icahn School of Medicine at Mount Sinai
    Inventors: Barbara Slusher, David Volsky, Mike Nedelcovych, Kristen Hollinger, Atsushi Kamiya
  • Publication number: 20210260179
    Abstract: In one aspect, provided herein is a mosaic influenza virus hemagglutinin (HA) polypeptide comprising an influenza A virus HA ectodomain of an influenza A virus strain HA, wherein the HA ectodomain comprises an HA stem domain of the influenza A virus strain HA and an HA globular head domain of the influenza A virus strain HA, wherein the HA globular head domain of the influenza A virus strain HA has been engineered to comprise one or more amino acid substitutions in one, two, three, four or all of the antigenic sites. In another aspect, provided herein are immunogenic compositions comprising such a mosaic influenza virus HA polypeptide or an influenza A virus comprising such a mosaic influenza virus HA polypeptide. In yet another aspect, provided herein are methods for immunizing a subject against an influenza A vims in a subject comprising administering such an immunogenic composition to the subject.
    Type: Application
    Filed: June 20, 2019
    Publication date: August 26, 2021
    Applicant: ICAHN SCHOOL OF MEDICINE AT MOUNT SINAI
    Inventors: Adolfo GARCIA-SASTRE, Peter PALESE, Florian KRAMMER, Felix BRÖCKER, Weina SUN
  • Patent number: 11101021
    Abstract: An example method of diagnosing chronic kidney disease (CKD) includes obtaining an electronic medical record for a patient having medical data. The medical data includes an indication if the patient had been previously diagnosed with CKD, an indication if the patient had previously undergone a kidney transplant, an indication if the patient had previously undergone a renal dialysis procedure, an indication if the patient had previously been diagnosed with another type of kidney disease, one or more glomerular filtration rate (GFR) measurements associated with the patient, an indication if the patient has type 2 diabetes, and/or an indication if the patient has hypertension. The method also includes automatically determining that the patient has CKD or does not have CKD based on the medical data in the electronic record.
    Type: Grant
    Filed: July 31, 2015
    Date of Patent: August 24, 2021
    Assignee: Icahn School of Medicine at Mount Sinai
    Inventors: Girish Nadkarni, Omri Gottesman, Stephen Bartlett Ellis, Erwin Bottinger
  • Patent number: 11098361
    Abstract: A method for identifying the risk of developing Chronic Allograft Nephropathy (CAN) in a patient that received a kidney transplant from a donor which comprises identifying the race of the donor; determining the levels of SHROOM 3 expression in a kidney biopsy specimen obtained from the patient at a predetermined time after transplant; comparing the level of SHROOM 3 expression in the biopsy specimen with the levels of SHROOM 3 expression in a control; determining if the level of SHROOM 3 expression in the allograft is significantly higher than in the control, and diagnosing the patient as being at risk for CAN if the level of SHROOM 3 expression in the specimen is significantly higher than in the control.
    Type: Grant
    Filed: March 10, 2014
    Date of Patent: August 24, 2021
    Assignee: Icahn School of Medicine at Mount Sinai
    Inventors: Barbara Murphy, John Cijiang He
  • Publication number: 20210247394
    Abstract: The present invention relates to methods of using bacterial strain 1687A6 in detecting, diagnosing and treating disease or disorders of the GI tract. The present invention also relates to modulating the immune responses of an individual by inducing Th17 cell differentiation, proliferation, or accumulation. Further, the invention relates to therapeutic compositions containing strain 1687A6 or compounds derived from it and methods for treating disease in a subject using such compositions.
    Type: Application
    Filed: April 19, 2019
    Publication date: August 12, 2021
    Applicant: Icahn School of Medicine at Mount Sinai
    Inventors: Graham BRITTON, Jeremiah FAITH, Zhihua LI, Ilaria MOGNO
  • Patent number: 11078496
    Abstract: The present invention relates to a system for F-box hormone receptor regulated protein expression in mammalian cells. The system includes a silencing nucleic acid molecule comprising a first promoter and an shRNA operably linked to the first promoter, where the shRNA silences expression of a target protein. The system also includes an expression nucleic acid molecule comprising a second promoter, an F-box hormone receptor operably linked to the second promoter, and a nucleic acid molecule encoding a fusion protein comprising a degron fused to the target protein, where the nucleic acid molecule encoding the fusion protein is operably linked to the second promoter. Also disclosed are vectors comprising the system of the present application and methods of use thereof.
    Type: Grant
    Filed: April 12, 2017
    Date of Patent: August 3, 2021
    Assignees: ICAHN SCHOOL OF MEDICINE AT MOUNT SINAI, UNIVERSITY OF WASHINGTON THROUGH ITS CENTER FOR COMMERCIALIZATION
    Inventors: Ran Brosh, Sr., Ihor R. Lemischka, Ning Zheng
  • Patent number: 11078494
    Abstract: The invention provides a method for generating a transgenic eukaryotic cell population having a modified human Rosa26 locus, which method includes introducing a functional DNA sequence into the human Rosa26 locus of starting eukaryotic cells. Also provided are targeting vectors useful in the method, as well as a cell population and a transgenic non-human animal comprising a modified human Rosa26 locus. Finally, the invention provides an isolated DNA sequence corresponding to the human Rosa26 locus.
    Type: Grant
    Filed: October 25, 2019
    Date of Patent: August 3, 2021
    Assignee: ICAHN SCHOOL OF MEDICINE AT MOUNT SINAI
    Inventors: Gordon Keller, Stefan Irion, Herve Luche, Paul Gadue, Hans J. Fehling
  • Patent number: 11066370
    Abstract: The present invention relates to a compound having the structure of formula (I) or a stereoisomer, pharmaceutically acceptable salt, oxide, or solvate thereof, where X, Y, Z, R, R1, R2, R3, R4, R5, and R6 are as described herein. The present invention also relates to compositions containing the compound having the structure of formula (I), and a method of treating cancer in a subject.
    Type: Grant
    Filed: November 14, 2019
    Date of Patent: July 20, 2021
    Assignee: ICAHN SCHOOL OF MEDICINE AT MOUNT SINAI
    Inventors: Arvin C. Dar, Ross L. Cagan, Alex P. Scopton, Masahiro Sonoshita
  • Patent number: 11068799
    Abstract: Systems and method for perturbing a system include obtaining directed acyclic/cyclic graph candidates {GI, . . . , GN} for the system. Each Gi in {Gj, . . . GN} includes a causal relationship between a parent and child node. {GI, GN} demonstrate Markov equivalence. Observed data D is obtained for the nodes. For each respective Gi, the marginal probability of a parent node xi in Gi is clamped by D while computing a distribution of marginal probabilities for a child node yi, by Bayesian network or Dynamic Bayesian network belief propagation using an interaction function. The observed distribution for the child node yi, in D and the computed distribution of marginal probabilities for the child node yi are scored using a nonparametric function, and such scores inform the selection of a directed/cyclic graph from {GI, . . . , GN}. The system is perturbed using a perturbation that relies upon a causal relationship in the selected directed acyclic/cyclic graph.
    Type: Grant
    Filed: September 3, 2015
    Date of Patent: July 20, 2021
    Assignee: ICAHN SCHOOL OF MEDICINE AT MOUNT SINAI
    Inventors: Rui Chang, Eric E. Schadt
  • Publication number: 20210198323
    Abstract: Described herein are recombinant Newcastle disease viruses (“NDVs”) comprising a packaged genome, wherein the packaged genome comprises a transgene encoding a respiratory syncytial virus (“RSV”) F protein or human metapneumovirus (“hMPV”) F protein. Also described herein are recombinant NDVs comprising a packaged genome, wherein the packaged genome comprises a transgene encoding a chimeric F protein, wherein the chimeric F protein comprises (i) an RSV F protein ectodomain and NDV F protein transmembrane and cytoplasmic domains; or (ii) an hMPV F protein ectodomain and NDV F protein transmembrane and cytoplasmic domains. The recombinant NDVs and compositions thereof are useful for the immunizing against RSV or hMPV as well as the prevention of RSV disease or hMPV disease.
    Type: Application
    Filed: August 16, 2019
    Publication date: July 1, 2021
    Applicants: ICAHN SCHOOL OF MEDICINE AT MOUNT SINAI, RUTGERS, THE STATE UNIVERSITY OF NEW JERSEY
    Inventors: Joan E. DURBIN, Russell K. DURBIN, Adolfo GARCIA-SASTRE, Ignacio MENA, Peter PALESE
  • Patent number: 11044896
    Abstract: This invention relates to a transgenic non-human mammal whose genome comprises a polynucleotide sequence encoding a T cell receptor that is specific to a fluorescent protein, where the T cell of the non-human mammal comprises the T cell receptor. The present invention also relates to an isolated T cell from the transgenic non-human mammal of the present invention, an isolated T cell comprising an expression construct comprising a polynucleotide sequence that encodes a T cell receptor that is specific to a fluorescent protein, methods of making transgenic non-human mammals comprising T cell receptors that are specific to a fluorescent protein, a method of depleting cells in a non-human mammal using isolated T cells that encode a T cell receptor that is specific to a target protein, and a method of characterizing a T cell response to an agent.
    Type: Grant
    Filed: September 12, 2014
    Date of Patent: June 29, 2021
    Assignee: ICAHN SCHOOL OF MEDICINE AT MOUNT SINAI
    Inventors: Brian Brown, Judith Agudo
  • Patent number: 11034761
    Abstract: The present disclosure provides compositions and methods for reducing adiposity by inhibiting FSH/FHSR in a subject in need thereof.
    Type: Grant
    Filed: July 24, 2017
    Date of Patent: June 15, 2021
    Assignee: ICAHN SCHOOL OF MEDICINE AT MOUNT SINAI
    Inventor: Mone Zaidi
  • Publication number: 20210169883
    Abstract: The present invention provides orexin receptor antagonists for use in treating aggression in a subject. The orexin receptor antagonists can have selective affinity for orexin receptor 1 (Ox1R) or for orexin receptor 2 (Ox2). The orexin receptor antagonists can also have dual affinity for both Ox1R and Ox2R, wherein their affinities can be the same or different. The present invention also provides pharmaceutical compositions and kits comprising orexin receptor antagonists for treating aggression or for treating psychiatric disorders with an aggression component.
    Type: Application
    Filed: July 25, 2019
    Publication date: June 10, 2021
    Applicant: Icahn School of Medicine at Mount Sinai
    Inventors: Meghan Flanigan, Scott Russo
  • Patent number: 11028392
    Abstract: The invention relates to double-stranded ribonucleic acid (dsRNA) compositions targeting the ALAS1 gene, and methods of using such dsRNA compositions to alter (e.g., inhibit) expression of ALAS1.
    Type: Grant
    Filed: September 20, 2018
    Date of Patent: June 8, 2021
    Assignees: Alnylam Pharmaceuticals, Inc., ICAHN SCHOOL OF MEDICINE AT MOUNT SINAI
    Inventors: Brian Bettencourt, Kevin Fitzgerald, William Querbes, Robert J. Desnick, Makiko Yasuda
  • Publication number: 20210161674
    Abstract: The present invention includes a method for generating a three-dimensional model of a bone and generating a cut plan for excavating a portion of the bone according to the cut plan to allow the insertion of a custom implant. In a particular arrangement, the method also includes excavating the bone with an autonomous extremity excavator utilizing the cut plan generated by a processor. In a further arrangement, the method includes generating a digital model of a custom implant and generating, using the digital model, a physical model sharing the same dimensions as the digital module using manufacturing device.
    Type: Application
    Filed: February 16, 2021
    Publication date: June 3, 2021
    Applicant: ICAHN SCHOOL OF MEDICINE AT MOUNT SINAI
    Inventors: DOUGLAS B. UNIS, SULAIMAN SOMANI, ANTHONY B. COSTA
  • Publication number: 20210145959
    Abstract: The present disclosure is directed towards chimeric glycoproteins wherein the clip region, a core region, a flap region, and a transmembrane and cytoplasmic domain are defined by starting from the amino terminus of the protein, these domains are comprised of the following amino acid residue ranges: clip, 1 through 40 to 60; core, 40 to 60 through 249 to 281; flap, 249 to 281 through 419 to 459; the transmembrane domain is comprised of amino acids 460 through 480, and the remaining amino acids 481 through 525 comprise the cytoplasmic domain; and wherein the clip, core, flap, transmembrane, and cytoplasmic domain comprise a chimeric combination of at least two lyssavirus, wherein the chimeric glycoprotein is advantageously inserted into a rabies-based vaccine vector.
    Type: Application
    Filed: June 13, 2018
    Publication date: May 20, 2021
    Applicants: Thomas Jefferson University, ICAHN School of Medicine at Mount Sinai
    Inventors: Schnell Matthias, Christine Rettew Fisher, Christoph Wirblich, Gene Tan
  • Publication number: 20210145360
    Abstract: Systems and methods for treating a subject with a psychiatric disorder are provided in which a therapy session is conducted. In the therapy session, each respective expression image in a plurality of expression images is sequentially displayed. Each expression image is independently associated with an expression. The successive display of images is construed as a tiled series of expression image subsets, each consisting of N expression images. Upon completion of the display of each respective subset, the user is challenged as to whether the first and the last images in the respective subset exhibit the same emotion. A score is determined for the respective subset based on whether the subject learned to respond correctly. The number of images in each subset is adjusted to a new number based on these scores. A treatment regimen is prescribed to the subject for the psychiatric disorder based at least in part on the scores.
    Type: Application
    Filed: January 22, 2021
    Publication date: May 20, 2021
    Applicant: Icahn School of Medicine of Mount Sinai
    Inventors: Brian IACOVIELLO, Dennis CHARNEY
  • Patent number: 10988779
    Abstract: The present disclosure relates to viral delivery of RNA utilizing self-cleaving ribozymes and applications of such, including but not limited to CRISPR-Cas related applications.
    Type: Grant
    Filed: June 22, 2017
    Date of Patent: April 27, 2021
    Assignee: Icahn School of Medicine at Mount Sinai
    Inventors: Arnold Park, Benhur Lee, Ruth Watkinson
  • Patent number: 10988737
    Abstract: The present invention provides a simple and robust human liver cell-based system in which persistent hepatitis C infection, persistent hepatitis B infection or ethanol exposure induces a clinical Prognostic Liver Signature (PLS) high-risk gene signature. The cellular model system for hepatocellular carcinoma (HCC)/cirrhosis development and progression may be used in the screening of compounds useful in the treatment and/or prevention of cirrhosis and/or HCC as well as in the identification biomarkers for the prediction of liver disease (especially cirrhosis) progression and HCC. The present invention also relates to specific compounds that have been identified, using such screening methods, as useful in the treatment and/or the prevention of HCC/cirrhosis.
    Type: Grant
    Filed: April 28, 2016
    Date of Patent: April 27, 2021
    Assignees: Universite de Strasbourg, Institut National de la Sante et de la Recherche Medicale Institut, Hospitalier Universitaire de Strasbourg, ICAHN School of Medicine at Mount Sinai
    Inventors: Thomas Baumert, Yujin Hoshida
  • Publication number: 20210085655
    Abstract: Disclosed herein are controlled release compositions comprising riluzole and the uses thereof.
    Type: Application
    Filed: September 19, 2020
    Publication date: March 25, 2021
    Applicant: Icahn School of Medicine at Mount Sinai
    Inventor: Ana Pereira